Table 1.
Study Participant Clinical and Demographic Data
| Record ID | Age at Enrollment (years) | Race | Ethnicity | Sex | Gender Identity | COVID Vaccine Received | Anti-Spike Serology at Entry | Year of HIV Diagnosis | Year started multi-agent ART | Most recent CD4 (cells/ul) | Nadir CD4 if known (cells/uL) | Current ART |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2 | 68 | White | Hispanic or Latinx | Male | Man | BNT162b2 | Not Detected | 1993 | 1993 | 542 | unknown | TAF/FTC, DTG |
| 3 | 52 | White | Hispanic or Latinx | Female | Woman | BNT162b2 | Not Detected | 2006 | 2006 | 994 | unknown | TAF/FTC/BIC |
| 4 | 36 | White | Not Hispanic or Latinx | Male | Man | BNT162b2 | Not Detected | 2011 | 2011 | 1,115 | unknown | ABC/3TC/DTG |
| 5 | 32 | Black or African American, White | Not Hispanic or Latinx | Male | Man | BNT162b2 | Not Detected | 2008 | 2008 | 692 | 10 | TAF/FTC/c/EVG |
| 6 | 45 | White | Not Hispanic or Latinx | Male | Man | BNT162b2 | Detected | 2010 | 2010 | 583 | 6 | TAF/FTC/BIC |
| 7 | 27 | White | Hispanic or Latinx | Male | Man | BNT162b2 | Not Detected | 2018 | 2018 | 591 | 571 | TAF/FTC/BIC |
| 8 | 51 | Black or African American | Not Hispanic or Latinx | Male | Man | BNT162b2 | Not Detected | 2003 | 2008 | 154 | 12 | TAF/FTC/c/EVG |
| 9 | 61 | Black or African American | Not Hispanic or Latinx | Male | Man | BNT162b2 | Not Detected | 1994 | 1996 | 574 | unknown | TAF/FTC/c/DRV |
| 12 | 29 | White | Not Hispanic or Latinx | Male | Man | BNT162b2 | Detected | 2016 | 2016 | 760 | 640 | TAF/FTC/c/EVG |
| 13 | 46 | White | Not Hispanic or Latinx | Male | Man | mRNA 1273 | Not Detected | 2015 | 2015 | 893 | 276 | ABC/3TC/DTG |
| 14 | 52 | Asian, White | Not Hispanic or Latinx | Male | Man | BNT162b2 | Not Detected | 1993 | 1995 | 167 | unknown | TAF/FTC, DTG |
| 15 | 49 | Black or African American | Not Hispanic or Latinx | Female | Woman | BNT162b2 | Not Detected | 2005 | 2007 | 546 | unknown | TAF/FTC/c/EVG |
| 17 | 62 | Black or African American | Not Hispanic or Latinx | Male | Transgender Woman | BNT162b2 | Not Detected | 2004 | 2004 | 844 | 282 | TAF/FTC/BIC |
| 0518 | 65 | NA | South Asian | Male | Man | BNT162b2 | Detected | 1987 | 1996 | 760 | 10 | FTC/DTG/TAF |
| 0520 | 60 | NA | White or Caucasian | Male | Man | BNT162b2 | Not Detected | 2016 | 2015 | 1230 | 900 | 3TC/DTG |
| 0528 | 28 | NA | White or Caucasian | Male | Man | BNT162b2 | Not Detected | 2017 | 2020 | 830 | 540 | 3TC/DTG |
| 0529 | 28 | NA | White or Caucasian | Male | Man | BNT162b2 | Not Detected | 2016 | 2016 | 1100 | 320 | 3TC/ABA/DTG |
| 0532 | 29 | NA | Latin American | Male | Man | BNT162b2 | Not Detected | 2017 | 2017 | 780 | 480 | 3TC/ABA/DTG |
| 0534 | 48 | NA | White or Caucasian | Male | Man | BNT162b2 | Not Detected | 1991 | 2010 | 620 | 260 | 3TC/ABA/DTG |
| 0537 | 48 | NA | Arab | Male | Man | BNT162b2 | Detected | 2018 | 2018 | 740 | 420 | 3TC/DTG |
| 0538 | 25 | NA | Filipino | Male | Man | BNT162b2 | Not Detected | 2019 | 2019 | 460 | 400 | TDF/FTC/DTG |
| 0541 | 40 | NA | Middle Eastern | Male | Man | BNT162b2 | Not Detected | 2017 | 2020 | 1010 | 1010 | FTC/EGV/COB/TAF |
| 0543 | 32 | NA | White or Caucasian | Male | Man | BNT162b2 | Not Detected | 2018 | 2018 | 970 | 490 | FTC/TAF/BCG |
| 0551 | 51 | NA | White or Caucasian | Male | Man | BNT162b2 | Detected | 2009 | 2010 | 1110 | 560 | FTC/TAF/BCG |
| 0562 | 60 | NA | White or Caucasian | Female | Woman | BNT162b2 | Not Detected | 1995 | 1999 | 920 | 110 | 3TC/ABA/ATA |
| 0565 | 36 | NA | Middle Eastern | Male | Man | BNT162b2 | Not Detected | 2016 | 2020 | 590 | 420 | FTC/TAF/BCG |
| 0574 | 61 | NA | White or Caucasian | Male | Man | BNT162b2 | Not Detected | 1989 | 2011 | 1160 | 550 | TDF/FTC/MKS |
| 0575 | 34 | NA | Chinese | Male | Man | BNT162b2 | Not Detected | 2017 | 2015 | 489 | 330 | FTC/TAF/BCG |
| 0579 | 38 | NA | White or Caucasian | Male | Non-binary or similar identity | BNT162b2 | Not Detected | 2001 | 2016 | 1800 | 700 | 3TC/ABA/DTG |
| 0585 | 33 | NA | Chinese | Male | Man | BNT162b2 | Not Detected | 2011 | 2011 | 840 | 10 | DMP/TDF/FTC |
| 0601 | 52 | NA | White or Caucasian | Male | Man | BNT162b2 | Not Detected | NA | 2010 | 1560 | 520 | 3TC/NEV/ABA |
| 0602 | 38 | NA | Chinese | Male | Man | BNT162b2 | Not Detected | 2003 | 2005 | 800 | 170 | FTC/TAF/BCG |
| 0605 | 32 | NA | Latin American | Male | Man | BNT162b2 | Not Detected | 2016 | 2016 | 440 | 290 | 3TC/ABA/DTG |
| 0620 | 33 | NA | Southeast Asian | Female | Woman | BNT162b2 | Not Detected | 2016 | 2020 | 870 | 750 | FTC/TAF/BCG |
| 0622 | 37 | NA | White or Caucasian | Female | Woman | BNT162b2 | Not Detected | 2003 | 2007 | 320 | 160 | TDF/FTC/DRV/COB |
ABC abacavir, BIC bictegravir, c obicistat, DRV darunavir, DTG dolutegravir, EVG elvitegravir, FTC emtricitabine, RPV rilpivirine, TAF tenofovir alafenamide, 3TC lamivudine.